Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01035502 · ClinicalTrials.gov registry record · Phase 2
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
A Phase 2 study, sponsored by Clavis Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT01035502 is a Phase 2 study that has completed, run by Clavis Pharma. The registered enrollment target is 51 participants.
The verdict
NCT01035502, a Phase 2 study, has completed, sponsored by Clavis Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The main objective of this study is to assess the biological activity of elacytarabine in combination with idarubicin in patients with acute myeloid leukaemia who has failed the first course of a remission-induction treatment with cytarabine (ara-C). In addition, the correlation between hENT1 (human equilibrative nucleoside transporter 1) and overall survival will be studied.
Interventions
- DRUG Elacytarabine plus idarubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01035502
The ClinicalTrials.gov registry entry for NCT01035502 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clavis Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Elacytarabine plus idarubicin is the first listed.
NCT01035502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01035502 about?
NCT01035502 is a clinical study titled "A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia". The main objective of this study is to assess the biological activity of elacytarabine in combination with idarubicin in patients with acute myeloid leukaemia who has failed the first course of a remission-induction treatment with cytarabine (ara-C). In addition, the correlation between hENT1 (human...
What is the current status of trial NCT01035502?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2009-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01035502?
The interventions under investigation include: Elacytarabine plus idarubicin (DRUG).
Who is sponsoring clinical trial NCT01035502?
This trial is sponsored by Clavis Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.